Impact of Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy on Endogenous Fibrinolysis in Acute Coronary Syndrome: The VaLiDate-R study
Research output: Contribution to journal › Article › peer-review
1Citation
(Scopus)
57Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Impact of Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy on Endogenous Fibrinolysis in Acute Coronary Syndrome: The VaLiDate-R study'. Together they form a unique fingerprint.